Reset IV carries a September 2025 federal warning letter whose opening line cites its own website. It is a mobile infusion service rather than a compounder, it prices NAD+ by the milligram per visit in a handful of named cities, and the only place its company name appears is that federal letter.
What Reset IV charges
NAD+: $299 — per visit; there is no subscription and no billing period
NAD+: $499 — per visit; there is no subscription and no billing period
NAD+: $749 — per visit; there is no subscription and no billing period
NAD+: $999 — per visit; there is no subscription and no billing period
Glutathione: $59 — per session as an add-on on the pricing page; the seller's own add-on page prices the same thing at $75, twice
Reset IV is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
The letter publishes a company name the website does not
The 2025 letter opens by citing this seller's own web address, and its recipient block names Reset IV, LLC doing business as Reset IV, at a Las Vegas address in one of the cities the site itself serves.
No legal entity appears anywhere on the site — no LLC, no Inc, no copyright line on the home, contact or about pages.
So a reader who wants to know who they are buying from has to read the enforcement record to find out.
Priced by the milligram, and by the visit
It publishes four NAD+ doses with the milligrams printed on each and an infusion time attached to every one, from a couple of hours at the smallest dose to over four at the largest.
Each is a per-visit charge. There is no subscription, no billing period, and the site says there is no travel fee.
Its glutathione add-on is published at two different figures on two of its own pages, and both are recorded here. Neither is corrected, because the seller has not corrected it.
Two of its own pages disagree about the dose menu
Its NAD+ therapy page says it offers infusions in two doses and directs readers to call for pricing.
Its pricing page publishes four doses, each with a figure.
Both sentences are the seller's. This review records the four published doses and notes that the seller's own therapy page describes a narrower menu than its pricing page sells.
A blend's price sits directly under the NAD+ heading
The NAD+ therapy page prints a flat price beneath an ingredient table for a product whose three ingredients are saline, NAD+ and glutathione.
A reader skimming that page would take that figure for the NAD+ price; it is the blend's, so it is not filed here. Its ten-ingredient drip is likewise not filed.
This is not a compounding pharmacy and does not present itself as one — it describes licensed nurses bringing IV hydration therapy to your door — and it publishes no compounding, FDA or pharmacy statement of any kind.
Who it's for
Readers in Las Vegas, Miami, Fort Lauderdale, Los Angeles or Orange County.
Buyers who want NAD+ priced by the milligram rather than by the month.
Shoppers who want the infusion time stated before they book.
Anyone who prefers paying per visit with no subscription attached.
Who should look elsewhere
Readers who will not buy from a seller carrying a federal warning letter.
Buyers outside the five cities it names.
Anyone who expects the company's legal name printed on its own website.
Shoppers who want a compounding or pharmacy statement before ordering.
Strengths
Prices NAD+ at four separate doses with the milligrams printed on each
States the infusion time beside every dose
Charges per visit with no subscription and says there is no travel fee
Names the cities it serves rather than implying national coverage
Trade-offs
Carries a 2025 federal warning letter naming its own website
Publishes no legal entity anywhere on the site; the federal letter is where the company name appears
Prices its glutathione add-on at two different figures on two of its own pages
Prints a blend's flat price directly under its NAD+ heading, where it reads like the NAD+ price
FDA disclosure
Reset IV received an FDA warning letter issued September 2025. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
How we verified this
Read the pricing page dose by dose and recorded each NAD+ figure with its milligrams and its infusion time as a per-visit charge, not a monthly one.
Read the add-on page and the pricing page together, found the same add-on published at two different figures, and recorded both.
Read the flat price under the NAD+ heading against the ingredient table beside it, identified it as a three-ingredient blend, and filed it against neither compound.
Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
Confirmed the federal warning letter from the letter's own opening line, which names this seller's website, and matched its recipient city against one of the cities the site itself serves.
A provider to compare Reset IV against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Yes, issued in September 2025. Its opening line cites this seller's own website, and its recipient block names the company at a Las Vegas address.
Is this a monthly programme?
No. Every figure is a per-visit charge for a single infusion. There is no subscription and no billing period, and the site says there is no travel fee.
How much NAD+ do I get?
The pricing page publishes four doses with the milligrams printed on each and an infusion time beside every one. Its therapy page describes a narrower two-dose menu and directs readers to call, which the seller has not reconciled.
Who runs it?
The site publishes no legal entity anywhere. The company name appears in the federal warning letter's recipient block, not on the seller's own pages.
Reset IV is not a paid partner; this link may earn a commission if that changes. Full disclosure.